OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)

被引：0
|
作者：
Negrier, S. [1 ]
Figlin, R. A. [2 ]
Hutson, T. E. [3 ]
Tomczak, P. [4 ]
Michaelson, M. D. [5 ]
Bukowski, R. M. [6 ]
Huang, X. [7 ]
Kim, S. T. [7 ]
Chen, I. [7 ]
Motzer, R. J. [8 ]
机构：
[1] Ctr Leon Berard, Cytokines & Canc Res Unit, F-69373 Lyon, France
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Baylor Sammons Texas Oncol PA, Dallas, TX USA
[4] Klin Onkol Oddzial Chernioterapii, Poznan, Poland
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[7] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [1] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Negrier, S.
    Oudard, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I
    Motzer, R. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [3] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    Motzer, R. J.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Bjarnason, G. A.
    Kim, S. T.
    Chen, I.
    Michaelson, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia
    Godoy, J., I
    Cardona, A. F.
    Alvis, N.
    Arango, C. H.
    Romero, M.
    Spath, A.
    Ramirez, P.
    Caceres, H. A.
    Quijano, M. F.
    VALUE IN HEALTH, 2008, 11 (03) : A100 - A100
  • [6] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
  • [7] Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
    Motzer, R. J.
    Michaelson, M. D.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 301 - 301
  • [8] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
  • [9] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
    Cella, D.
    Michaelson, M. D.
    Cappelleri, J. C.
    Bushmakin, A. G.
    Charbonneau, C.
    Kim, S. T.
    Li, J. Z.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345